Thursday, April 23, 2026
← Back to archivePolicy
Policy•STAT News•Apr 23, 2026
Opinion: Kennedy’s new silence on vaccines is political — and it won’t last
background ▾
- •Kennedy has implemented structural changes to federal vaccine advisory processes (ACIP reconstitution, schedule changes) that are currently blocked by court order in American Academy of Pediatrics et al. v. Kennedy, creating immediate uncertainty for clinical practice and payer coverage recommendations
- •The observed reduction in Kennedy's public anti-vaccine messaging is characterized as electoral positioning ahead of midterms rather than a genuine policy reversal, suggesting renewed acceleration of vaccine policy changes is likely post-election
- •These developments have disrupted federal advisory processes and created uncharted territory for clinicians and payers regarding vaccine coverage and recommendations, particularly for the respiratory season ahead
MMR vaccineCOVID-19 vaccine
→ Read original articlePolicy•Fierce Pharma•Apr 23, 2026
AbbVie to establish NC production base with $1.4B investment, creating 730-plus jobs
background ▾
- •AbbVie commits $1.4B to North Carolina manufacturing with 730+ job creation, signaling continued domestic production investment
- •Timing suggests alignment with U.S. reshoring initiatives and supply chain security priorities
AbbVie
→ Read original articlePolicy•Fierce Pharma•Apr 23, 2026
CMS delays Part D GLP-1 model amid skepticism from insurers
background ▾
- •CMS voluntary GLP-1 access model delayed due to insurer resistance, signaling potential need for policy redesign
- •Insurers' opposition reflects broader concerns about GLP-1 cost burden and reimbursement sustainability in Part D
- •Watch for revised CMS proposal and how administration balances GLP-1 access expansion with payer profitability concerns
CMSGLP-1 receptor agonists
→ Read original articlePolicy•Fierce Pharma•Apr 23, 2026
Samsung Biologics posts massive revenue growth as labor union rally sets strike in motion
background ▾
- •Samsung Biologics faces an organized labor strike that could disrupt manufacturing operations for a major global CDMO
Samsung Biologics
→ Read original articlePolicy•Endpoints News•Apr 23, 2026
Sanofi defends Garijo appointment, says it is 'fully committed' to immunology
background ▾
- •Sanofi leadership is actively defending the Garijo CEO appointment and reassuring stakeholders about immunology commitment, suggesting notable investor concern about strategic direction under new management
- •The timing of this narrative management during earnings—just before the new CEO officially takes over—indicates potential concerns about perceived shifts away from immunology as a core focus area
Sanofi
→ Read original articleMarket Access
Market Access•Fierce Pharma•Apr 23, 2026
Amneal seizes 'golden era' for biosims with $1.1B Kashiv buyout
background ▾
- •Amneal's $1.1B Kashiv acquisition signals aggressive biosimilars consolidation as the market matures and competition intensifies
- •Amneal leadership explicitly frames biosimilars as entering a 'golden era,' indicating confidence in market growth and commercial opportunity despite pricing pressure
- •Watch for: Kashiv's biosimilar pipeline readouts, regulatory approvals for acquired programs, and Amneal's ability to achieve synergies in an increasingly crowded market
Amneal PharmaceuticalsKashiv BioSciences
→ Read original articleMarket Access•Fierce Biotech•Apr 22, 2026
Merck goes with Google for AI push, striking enterprise partnership worth up to $1B
background ▾
- •Merck's $1B Google Cloud AI partnership signals enterprise-scale commitment to agentic AI across entire value chain—R&D to commercial—with embedded vendor engineering support, not merely software licensing
- •The timing of this AI investment coincides with aggressive cost-cutting ($3 billion savings target by 2027), major restructuring (oncology-focused reorganization), and $10+ billion in recent M&A acquisitions, suggesting AI is seen as critical to integration and productivity gains amid organizational change
- •Watch for: Merck's ability to realize claimed ROI from the partnership; whether the AI deployment materially impacts R&D cycle times or manufacturing efficiency in measurable ways; and whether competitive pressure from Novo Nordisk's parallel OpenAI deal drives further consolidation of AI platform partnerships in Big Pharma
MerckGoogle CloudNovo Nordisk
→ Read original articleMarket Access•Fierce Pharma•Apr 23, 2026
Deerfield trots into pharma sales software space with CRM-enhancing tool
background ▾
- •Deerfield Group enters the pharma sales enablement software market with a CRM-enhancement tool targeting message compliance and sales rep alignment
Deerfield Group
→ Read original articleMarket Access•Fierce Pharma•Apr 23, 2026
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
background ▾
- •Merck committed $1 billion to Google Cloud partnership focused on AI-driven commercial and HCP engagement strategy
- •The deal represents a strategic pivot toward AI-enabled sales force effectiveness and personalized physician engagement
- •Success depends on execution and actual adoption by field teams; competitive responses from other pharma companies likely to follow
Merck & Co.Google Cloud
→ Read original articleMarket Access•Fierce Pharma•Apr 23, 2026
Novartis launches ‘Sjöut for Sjögren’s campaign, teams with Carrie Ann Inaba
background ▾
- •Novartis is investing in disease awareness marketing for Sjögren's syndrome using celebrity partnership to expand patient reach and market positioning
Novartis
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 23, 2026
Sanofi CFO defends Hudson’s Dupixent legacy, but accepts ‘number of setbacks’ in R&D
background ▾
- •Sanofi disclosed multiple recent R&D failures (amlitelimab, balinatunfib, itepekimab, meningococcal vaccine) alongside selective successes, revealing a pipeline with significant execution risk
- •New CEO Belén Garijo arrives with explicit board mandate to strengthen R&D governance and innovation, signaling potential portfolio reassessment beyond current four therapeutic priorities
- •Watch for Garijo's first strategic announcements on R&D restructuring, pipeline reprioritization, and whether Sanofi will expand or narrow its therapeutic focus areas
SanofiRegeneronMerck KGaADupixentamlitelimabbalinatunfib
→ Read original articleClinical Trials•Fierce Biotech•Apr 21, 2026
Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
background ▾
- •Miv-cel achieved clean sweep across all primary, secondary, and exploratory endpoints in KYSA-8, with unprecedented magnitude and consistency of functional improvement in a rare autoimmune disease with no approved treatments
- •All 26 trial patients achieved discontinuation of all immunomodulatory/immunosuppressant therapies by last follow-up, with significant reductions in pathogenic GAD65 autoantibodies, supporting the mechanism of immune reset
- •Duration of response beyond 16 weeks remains uncertain—critical for a purportedly 'once-and-done' CAR-T therapy; watch for FDA feedback on durability requirements and timeline for NDA submission
Kyverna Therapeuticsmiv-celmivocabtagene autoleucel
→ Read original articleClinical Trials•Endpoints News•Apr 21, 2026
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
background ▾
- •Roche's MS pill achieved >2x longer relapse-free interval versus Aubagio in Phase III, demonstrating meaningful clinical efficacy advantage
- •Hepatotoxicity signals warrant careful safety monitoring and could necessitate routine liver function testing in the label, affecting clinical convenience and adoption
- •Watch for regulatory feedback on safety profile during FDA review and how liver monitoring requirements compare to competitor standards (Aubagio, fingolimod, etc.)
RocheSanofiAubagio
→ Read original article